Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Aubagio

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,538Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Roche's Fenebrutinib Validates First BTK Inhibitor For MS
    Roche's Fenebrutinib Validates First BTK Inhibitor For MS

    03 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247014/0/en/Ad-hoc-announcement-pursuant-to-Art-53-LR-Roche-s-fenebrutinib-confirms-its-potential-as-first-and-only-BTK-inhibitor-for-relapsing-and-primary-progressive-MS-in-third-positive-Pha.html

    GLOBENEWSWIRE
    03 Mar 2026
    Share Share
    Roche's Experimental MS Drug Hits Main Goal in One of Two Trial
    Roche's Experimental MS Drug Hits Main Goal in One of Two Trial

    09 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251109262712/en/Genentechs-Fenebrutinib-Shows-Unprecedented-Positive-Phase-III-Results-as-the-Potential-First-and-Only-BTK-Inhibitor-in-Both-Relapsing-and-Primary-Progressive-Multiple-Sclerosis

    BUSINESSWIRE
    09 Nov 2025
    Share Share
    Enforcement Report - Week of April 16, 2025
    Enforcement Report - Week of April 16, 2025

    16 Apr 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-16-2025-39741.pdf

    FDA
    16 Apr 2025
    Share Share
    Concord Biotech approved by US FDA to market Teriflunomide
    Concord Biotech approved by US FDA to market Teriflunomide

    07 Apr 2025

    // BUSINESS STD

    https://www.business-standard.com/markets/capital-market-news/concord-biotech-gets-us-fda-nod-for-marketing-multiple-sclerosis-drug-teriflunomide-125040900207_1.html

    BUSINESS STD
    07 Apr 2025
    Share Share
    Torrent Pharma's Generic Teriflunomide Receives Approval in the U.S.
    Torrent Pharma's Generic Teriflunomide Receives Approval in the U.S.

    04 Apr 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209697

    FDA
    04 Apr 2024
    Share Share
    Merck KGaA suffers major blow as MS drug fails in late-stage trials
    Merck KGaA suffers major blow as MS drug fails in late-stage trials

    06 Dec 2023

    // Ludwig Burger REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/merck-kgaa-says-ms-drug-fails-late-stage-trials-2023-12-05/

    Ludwig Burger REUTERS
    06 Dec 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.